Amonafide Explained

Amonafide (originally AS1413) (INN, trade names Quinamed and Xanafide) was a drug that was being studied in the treatment of cancer. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential topoisomerase inhibitor and DNA intercalator.^{[1] [2]}

It was being developed as an anti-cancer therapy by Antisoma.^[3]

, it is in Phase III clinical trials.e.g. In March 2010 it is Phase III trial against secondary acute myeloid leukaemia (AML). In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.

See also

• Alrestatin

External links

• Amonafide entry in the public domain NCI Dictionary of Cancer Terms
• Clinical trials of amonafide at ClinicalTrials.gov

Notes and References

1. Allen SL, Lundberg AS . Amonafide: a potential role in treating acute myeloid leukemia . Expert Opinion on Investigational Drugs . 20 . 7 . 995–1003 . July 2011 . 21591994 . 10.1517/13543784.2011.585756 . 10999582 .
2. Freeman CL, Swords R, Giles FJ . Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia? . Expert Review of Hematology . 5 . 1 . 17–26 . February 2012 . 22272701 . 10.1586/ehm.11.68 . 26740617 .
3. Web site: Antisoma's Shares Plummet 70% as Cancer Candidate Bombs in Phase III NSCLC Trial . https://web.archive.org/web/20100401235144/http://www.genengnews.com/news/bnitem.aspx?name=78979622 . 1 April 2010 . 29 March 2010 . Genetic Engineering & Biotechnology News .